Ironwood Pharmaceuticals | IRWD - Assets


Ironwood Pharmaceuticals reported $434.57M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Almirall EUR 2.37B 29.97M Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amarin USD 624.36M 21.4M Jun/2026
Ardelyx USD 504.51M 2.9M Mar/2026
Astellas Pharma JPY 3.69T 125.48B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Charles River Laboratories USD 7.53B 198.16M Jun/2026
Coherus Biosciences USD 191.18M 74.84M Jun/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Halozyme Therapeutics USD 2.58B 95.31M Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
Ironwood Pharmaceuticals USD 434.57M 37.66M Mar/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Lexicon Pharmaceuticals USD 268.82M 83.83M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Moderna USD 10.96B 527M Jun/2026
Myriad Genetics USD 638.9M 34.8M Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
PTC Therapeutics USD 3.25B 381.37M Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Takeda JPY 15.66T 210.16B Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025